Pear Therapeutics Inc
NASDAQ:PEAR
P/B
Price to Book Value
Price to Book Value (P/B) ratio is a valuation multiple that measures the market's valuation of a company relative to its book value. The P/B ratio is only considered useful in practice when applied to capital-intensive businesses.
Market Cap | P/B | ||||
---|---|---|---|---|---|
US |
P
|
Pear Therapeutics Inc
NASDAQ:PEAR
|
1.1m USD | 0 | |
US |
Veeva Systems Inc
NYSE:VEEV
|
32.7B USD | 7.1 | ||
US |
Cerner Corp
NASDAQ:CERN
|
27.9B USD | 7.1 | ||
US |
Change Healthcare Inc
NASDAQ:CHNG
|
9B USD | 2.7 | ||
AU |
Pro Medicus Ltd
ASX:PME
|
11.8B AUD | 74.3 | ||
JP |
M3 Inc
TSE:2413
|
1T JPY | 3.2 | ||
US |
Doximity Inc
NYSE:DOCS
|
5.4B USD | 5.9 | ||
US |
Inspire Medical Systems Inc
NYSE:INSP
|
4.7B USD | 8 | ||
SE |
Sectra AB
STO:SECT B
|
46.3B SEK | 33.3 | ||
US |
Vocera Communications Inc
NYSE:VCRA
|
2.8B USD | 17 | ||
US |
Goodrx Holdings Inc
NASDAQ:GDRX
|
2.7B USD | 4.3 |
P/B Forward Multiples
Forward P/B multiple is a version of the P/B ratio that uses forecasted equity for the P/B calculation. 1-Year, 2-Years, and 3-Years forwards use equity forecasts for 1, 2, and 3 years ahead, respectively.